» Articles » PMID: 30670982

Plasma MicroRNA Pair Panels As Novel Biomarkers for Detection of Early Stage Breast Cancer

Overview
Journal Front Physiol
Date 2019 Jan 24
PMID 30670982
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer is the second leading cause of cancer death among females. We sought to identify microRNA (miRNA) markers in breast cancer, and determine whether miRNA expression is predictive of early stage breast cancer. The paired panel of microRNAs is promising. Global miRNA expression profiling was performed on three pooling samples of plasma from breast cancer, benign lesion and normal, using next generation sequencing technology. Thirteen microRNAs (hsa-miR-21-3p, hsa-miR-192-5p, hsa-miR-221-3p, hsa-miR-451a, hsa-miR-574-5p, hsa-miR-1273g-3p, hsa-miR-152, hsa-miR-22-3p, hsa-miR-222-3p, hsa-miR-30a-5p, hsa-miR-30e-5p, hsa-miR-324-3p, and hsa -miR-382-5p) were subsequently validated using real-time quantitative reverse transcription-polymerase chain reaction (RT-qPCR) in a cohort of 53 breast cancer, 40 benign lesions and 38 normal cases. The pairwise miRNA ratios were calculated as biomarkers to classify breast cancer. According to the model used to predict breast cancer from benign lesions, a panel of five miRNA pairs had high diagnostic power with an AUC of 0.942. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of this model after 10-fold cross validation were 0.881, 0.775, 0.827, and 0.756, respectively. In addition, the other panels of miRNA pairs distinguishing the breast cancer from normal and non-cancer patients had good performance. Certain MicroRNA pairs were identified and deemed effective in breast cancer screening, especially when distinguishing cancer from benign lesions.

Citing Articles

Identification and evaluation of a serum microRNA panel to diagnose colorectal cancer patients.

Ng L, Sin R, Cheung D, Wong C, Lam C, Leung W Int J Cancer. 2024; 156(4):865-874.

PMID: 39244686 PMC: 11661512. DOI: 10.1002/ijc.35175.


The Role of Circulating MicroRNAs in the Prediction of Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer in the Indian Population.

Tripathi S, Mathaiyan J, Kayal S, Ganesh R Cureus. 2024; 16(5):e59553.

PMID: 38832155 PMC: 11144582. DOI: 10.7759/cureus.59553.


Organotypic 3D Cell-Architecture Impacts the Expression Pattern of miRNAs-mRNAs Network in Breast Cancer SKBR3 Cells.

Gastelum-Lopez M, Aguilar-Medina M, Garcia Mata C, Lopez-Gutierrez J, Romero-Quintana G, Bermudez M Noncoding RNA. 2023; 9(6).

PMID: 37987362 PMC: 10661268. DOI: 10.3390/ncrna9060066.


Integrative Analysis Reveals STC2 as a Prognostic Biomarker of Laryngeal Squamous Cell Carcinoma.

Zhong R, Zhan J, Zhang S Appl Biochem Biotechnol. 2023; 196(7):3891-3913.

PMID: 37792175 DOI: 10.1007/s12010-023-04727-z.


Plasma microRNA ratios associated with breast cancer detection in a nested case-control study from a mammography screening cohort.

Chiorino G, Petracci E, Sehovic E, Gregnanin I, Camussi E, Mello-Grand M Sci Rep. 2023; 13(1):12040.

PMID: 37491482 PMC: 10368693. DOI: 10.1038/s41598-023-38886-0.


References
1.
Molina R, Barak V, van Dalen A, Duffy M, Einarsson R, Gion M . Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol. 2005; 26(6):281-93. DOI: 10.1159/000089260. View

2.
Rosenberg R, Yankaskas B, Abraham L, Sickles E, Lehman C, Geller B . Performance benchmarks for screening mammography. Radiology. 2006; 241(1):55-66. DOI: 10.1148/radiol.2411051504. View

3.
Davoren P, McNeill R, Lowery A, Kerin M, Miller N . Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol. 2008; 9:76. PMC: 2533012. DOI: 10.1186/1471-2199-9-76. View

4.
Schetter A, Harris C . Plasma microRNAs: a potential biomarker for colorectal cancer?. Gut. 2009; 58(10):1318-9. DOI: 10.1136/gut.2009.176875. View

5.
Puliti D, Zappa M, Miccinesi G, Falini P, Crocetti E, Paci E . An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence. Eur J Cancer. 2009; 45(18):3166-71. DOI: 10.1016/j.ejca.2009.06.014. View